• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

在最佳药物治疗下的血管造影疾病进展和心血管事件残留风险: COURAGE 试验的观察结果。

Angiographic disease progression and residual risk of cardiovascular events while on optimal medical therapy: observations from the COURAGE Trial.

机构信息

University of British Columbia, Vancouver Hospital Research Pavilion, 828 W. 10th Avenue, Vancouver, BC, Canada.

出版信息

Circ Cardiovasc Interv. 2011 Dec 1;4(6):545-52. doi: 10.1161/CIRCINTERVENTIONS.110.960062. Epub 2011 Nov 1.

DOI:10.1161/CIRCINTERVENTIONS.110.960062
PMID:22045968
Abstract

BACKGROUND

The extent to which recurrent events in patients with stable coronary artery disease is attributable to progression of an index lesion originally ≥50% diameter stenosis (DS) but not revascularized or originally <50% DS is unknown during optimal medical therapy (OMT).

METHODS AND RESULTS

In the COURAGE (Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation) trial, 205 patients assigned to OMT plus percutaneous coronary intervention (PCI) and 284 patients assigned to OMT only had symptom-driven angiograms suitable for analysis. Percentages of patients in the OMT+PCI and OMT-only cohorts with index lesions originally <50% DS were 30% and 32%, respectively; 20% and 68% had index lesions originally ≥50% DS. In both groups, index lesions originally <50% or ≥50% DS represented <4% and <25% of all such lesions, respectively. The only angiographic predictor of myocardial infarction or acute coronary syndrome was the number of lesions originally ≥50% DS that had not been revascularized (odds ratio, 1.15; confidence limits, 1.01-1.31; P<0.04).

CONCLUSIONS

Lesions originally <50% DS were index lesions in one third of patients referred for symptom-driven repeat angiography, but represented <4% of all such lesions. Nonrevascularized lesions originally ≥50% DS were more often index lesions in OMT-only patients, but still represented a minority (<25%) of all such lesions. These findings underscore the need for improved therapies to arrest plaque progression and reliable strategies for selecting stenoses warranting PCI.

摘要

背景

在最佳药物治疗(OMT)期间,对于稳定型冠状动脉疾病患者中原本≥50%直径狭窄(DS)但未进行血运重建或原本<50% DS 的病变的复发性事件归因于病变进展的程度尚不清楚。

方法和结果

在 COURAGE(经皮冠状动脉介入治疗和强化药物治疗的临床结果评估)试验中,205 例接受 OMT+经皮冠状动脉介入治疗(PCI)和 284 例接受 OMT 的患者进行了适合分析的症状驱动性血管造影。OMT+PCI 和 OMT 组中原本<50% DS 的病变患者比例分别为 30%和 32%;分别有 20%和 68%的患者有原本≥50% DS 的病变。在这两组中,原本<50%或≥50% DS 的病变分别<4%和<25%。心肌梗死或急性冠状动脉综合征的唯一血管造影预测因素是未进行血运重建的原本≥50% DS 的病变数量(比值比,1.15;置信区间,1.01-1.31;P<0.04)。

结论

在因症状驱动而进行重复血管造影的患者中,原本<50% DS 的病变占三分之一,但仅占所有此类病变的<4%。原本≥50% DS 的未血运重建病变在仅接受 OMT 的患者中更常作为病变,但仍<25%。这些发现强调了需要改善斑块进展的治疗方法和可靠的策略来选择需要 PCI 的狭窄病变。

相似文献

1
Angiographic disease progression and residual risk of cardiovascular events while on optimal medical therapy: observations from the COURAGE Trial.在最佳药物治疗下的血管造影疾病进展和心血管事件残留风险: COURAGE 试验的观察结果。
Circ Cardiovasc Interv. 2011 Dec 1;4(6):545-52. doi: 10.1161/CIRCINTERVENTIONS.110.960062. Epub 2011 Nov 1.
2
Optimal medical therapy with or without percutaneous coronary intervention in older patients with stable coronary disease: a pre-specified subset analysis of the COURAGE (Clinical Outcomes Utilizing Revascularization and Aggressive druG Evaluation) trial.老年稳定型冠心病患者接受或不接受经皮冠状动脉介入治疗的优化药物治疗:COURAGE(利用血运重建和积极药物评估的临床结果)试验的预先指定亚组分析
J Am Coll Cardiol. 2009 Sep 29;54(14):1303-8. doi: 10.1016/j.jacc.2009.07.013.
3
Optimal medical therapy with or without percutaneous coronary intervention in women with stable coronary disease: A pre-specified subset analysis of the Clinical Outcomes Utilizing Revascularization and Aggressive druG Evaluation (COURAGE) trial.稳定型冠心病女性患者接受或不接受经皮冠状动脉介入治疗的优化药物治疗:利用血运重建和强化药物评估(COURAGE)试验的预先指定亚组分析
Am Heart J. 2016 Mar;173:108-17. doi: 10.1016/j.ahj.2015.07.020. Epub 2015 Jul 26.
4
Clinical progression of incidental, asymptomatic lesions discovered during culprit vessel coronary intervention.罪犯血管冠状动脉介入治疗期间发现的偶然、无症状病变的临床进展。
Circulation. 2005 Jan 18;111(2):143-9. doi: 10.1161/01.CIR.0000150335.01285.12. Epub 2004 Dec 27.
5
Impact of the presence and extent of incomplete angiographic revascularization after percutaneous coronary intervention in acute coronary syndromes: the Acute Catheterization and Urgent Intervention Triage Strategy (ACUITY) trial.经皮冠状动脉介入治疗后急性冠状动脉综合征患者不完全血管造影再血管化的存在及其程度的影响:急性导管插入术和紧急介入治疗分层策略(ACUITY)试验。
Circulation. 2012 May 29;125(21):2613-20. doi: 10.1161/CIRCULATIONAHA.111.069237. Epub 2012 May 1.
6
Prognostic importance of coronary anatomy and left ventricular ejection fraction despite optimal therapy: assessment of residual risk in the Clinical Outcomes Utilizing Revascularization and Aggressive DruG Evaluation Trial.尽管进行了最佳治疗,但冠状动脉解剖结构和左心室射血分数对预后的重要性:在临床结果利用血运重建和强化药物评估试验中评估残余风险。
Am Heart J. 2013 Sep;166(3):481-7. doi: 10.1016/j.ahj.2013.07.007. Epub 2013 Aug 2.
7
Predicting outcome in the COURAGE trial (Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation): coronary anatomy versus ischemia.预测 COURAGE 试验(经皮冠状动脉介入治疗与强化药物治疗的临床结果评估)的结局:冠状动脉解剖与缺血。
JACC Cardiovasc Interv. 2014 Feb;7(2):195-201. doi: 10.1016/j.jcin.2013.10.017. Epub 2014 Jan 15.
8
Prognostic value of angiographic lesion complexity in patients with acute coronary syndromes undergoing percutaneous coronary intervention (from the acute catheterization and urgent intervention triage strategy trial).接受经皮冠状动脉介入治疗的急性冠状动脉综合征患者血管造影病变复杂性的预后价值(来自急性导管插入术和紧急干预分诊策略试验)
Am J Cardiol. 2014 Dec 1;114(11):1638-45. doi: 10.1016/j.amjcard.2014.09.003. Epub 2014 Sep 18.
9
Patterns and intensity of medical therapy in patients undergoing percutaneous coronary intervention.经皮冠状动脉介入治疗患者的医学治疗模式和强度。
JAMA. 2011 May 11;305(18):1882-9. doi: 10.1001/jama.2011.601.
10
Optimal medical therapy with or without percutaneous coronary intervention to reduce ischemic burden: results from the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial nuclear substudy.采用或不采用经皮冠状动脉介入治疗的优化药物治疗以减轻缺血负担:来自利用血运重建和强化药物评估的临床结果(COURAGE)试验核子亚研究的结果
Circulation. 2008 Mar 11;117(10):1283-91. doi: 10.1161/CIRCULATIONAHA.107.743963. Epub 2008 Feb 11.

引用本文的文献

1
Clinical Predictors of the Rapid Progression and Revascularization of Coronary Non-Target Lesions: A Serial Angiographic Study.冠状动脉非靶病变快速进展和血管重建的临床预测因素:一项系列血管造影研究
Rev Cardiovasc Med. 2024 Jul 8;25(7):251. doi: 10.31083/j.rcm2507251. eCollection 2024 Jul.
2
Quantitative plaque characterisation and association with acute coronary syndrome on medium to long term follow up: insights from computed tomography coronary angiography.基于计算机断层扫描冠状动脉造影的中长期随访:定量斑块特征及其与急性冠状动脉综合征的关联
Cardiovasc Diagn Ther. 2022 Aug;12(4):415-425. doi: 10.21037/cdt-21-763.
3
Comparison of Characteristics and Outcomes of Veterans With Stable Ischemic Heart Disease Enrolled in the COURAGE Trial Versus the Veterans Affairs Clinical Assessment, Reporting, and Tracking Program.
比较 COURAGE 试验中稳定型缺血性心脏病退伍军人的特征和结局与退伍军人事务临床评估、报告和跟踪计划。
Am J Cardiol. 2022 Oct 1;180:1-9. doi: 10.1016/j.amjcard.2022.06.049. Epub 2022 Jul 30.
4
Comparison of coronary atherosclerotic disease burden between ST-elevation myocardial infarction and non-ST-elevation myocardial infarction: Non-culprit Gensini score and non-culprit SYNTAX score.比较 ST 段抬高型心肌梗死与非 ST 段抬高型心肌梗死的冠状动脉粥样硬化性疾病负担:罪犯 Gensini 评分和罪犯 SYNTAX 评分。
Clin Cardiol. 2021 Feb;44(2):238-243. doi: 10.1002/clc.23534. Epub 2020 Dec 28.
5
Use of High-Risk Coronary Atherosclerotic Plaque Detection for Risk Stratification of Patients With Stable Chest Pain: A Secondary Analysis of the PROMISE Randomized Clinical Trial.高危冠状动脉粥样硬化斑块检测在稳定型胸痛患者风险分层中的应用:PROMISE 随机临床试验的二次分析。
JAMA Cardiol. 2018 Feb 1;3(2):144-152. doi: 10.1001/jamacardio.2017.4973.
6
Flow Mediated Dilatation as a Biomarker in Vascular Surgery Research.血流介导的扩张作为血管外科研发生物标志物。
J Atheroscler Thromb. 2017 Aug 1;24(8):779-787. doi: 10.5551/jat.40964. Epub 2017 Jul 1.
7
Factors Associated With Coronary Artery Disease Progression Assessed By Serial Coronary Computed Tomography Angiography.通过系列冠状动脉计算机断层扫描血管造影评估的与冠状动脉疾病进展相关的因素。
Arq Bras Cardiol. 2017 May;108(5):396-404. doi: 10.5935/abc.20170049. Epub 2017 May 4.
8
Flow Mediated Dilatation and Progression of Abdominal Aortic Aneurysms.血流介导的扩张与腹主动脉瘤的进展
Eur J Vasc Endovasc Surg. 2017 Jun;53(6):820-829. doi: 10.1016/j.ejvs.2017.03.001. Epub 2017 Apr 14.
9
Prognostic Value of Noninvasive Cardiovascular Testing in Patients With Stable Chest Pain: Insights From the PROMISE Trial (Prospective Multicenter Imaging Study for Evaluation of Chest Pain).稳定型胸痛患者无创心血管检查的预后价值:来自PROMISE试验(胸痛评估前瞻性多中心成像研究)的见解
Circulation. 2017 Jun 13;135(24):2320-2332. doi: 10.1161/CIRCULATIONAHA.116.024360. Epub 2017 Apr 7.
10
Effect of Percutaneous Coronary Intervention on Survival in Patients with Stable Ischemic Heart Disease.经皮冠状动脉介入治疗对稳定型缺血性心脏病患者生存率的影响。
Curr Cardiol Rep. 2017 Feb;19(2):17. doi: 10.1007/s11886-017-0821-6.